THROMBOTIC AND BLEEDING RISK FACTORS IN ESSENTIAL THROMBOCYTHEMIA

THROMBOTIC AND BLEEDING RISK FACTORS IN ESSENTIAL THROMBOCYTHEMIA

Background. Thrombosis and hemorrhage are the main category of complications, that affects the overall survival (OS), quality of life and therapy option choice in essential thrombocythemia (ET). Molecular marker presence (JAK2V617F (JAK2+), MPL (MPL+), CALR (CALR1+-type 1, CALR2+-type 2) or its abse...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. A. Zhernyakova, I. S. Martynkevich, V. A. Shuvaev, L. B. Polushkina, M. S. Fominykh, V. Yu. Udal’eva, I. I. Zotova, D. I. Shiсhbabaeva, S. V. Voloshin, S. S. Бессмельцев, A. V. Chechetkin, K. M. Abdulkadyrov
Format:	Article
Language:	Russian
Published:	ABV-press 2017-06-01
Series:	Онкогематология
Subjects:	essential thrombocythemia janus kinase gene mutation (jak2v617f) calreticulin gene mutation myeloproliferative leukemia virus oncogene triple-negative status
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/239
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Primary myelofibrosis: own experience and news from diagnostic and treatment
by: K. M. Abdulkadyrov, et al.
Published: (2015-06-01)

A rare CALR exon 9 mutation p.E379Vfs*53 in AYA generation exhibits gain-of-function nature and can induce essential thrombocythemia; a case report
by: Keiki Nagaharu, et al.
Published: (2025-12-01)

All we know about polycythemia vera: literature review and own experience
by: K. M. Abdulkadyrov, et al.
Published: (2015-10-01)

Revised myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
by: Mohan B Agarwal, et al.
Published: (2018-01-01)

Relation of JAK2 V617F allele burden and coronary calcium score in patients with essential thrombocythemia
by: Drofenik Ajda, et al.
Published: (2024-10-01)

Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F‐Positive Myeloproliferative Neoplasms
by: Guangshuai Teng, et al.
Published: (2025-07-01)

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
by: M B Agarwal, et al.
Published: (2015-01-01)

Downregulated PTEN and aberrant JAK–STAT signal pathway in essential thrombocythemia patients
by: Lin Luo, et al.
Published: (2025-05-01)

Clinicopathological spectrum of BCR-ABL-Negative myeloproliferative neoplasms with correlation with janus-associated kinase 2 mutation
by: Roopa Dixith, et al.
Published: (2019-01-01)

Chronic lymphocytic leukemia and JAK2 V617F positive essential thrombocythemia: Distinct clonal diseases?
by: Deniz Çetin, et al.
Published: (2014-08-01)

An Unusual Case of Essential Thrombocythemia and Acute Kidney Injury: Case Report and Literature Review
by: Celia Rodríguez Tudero, et al.
Published: (2025-05-01)

Carotid artery stenting in JAK2 V617F-positive essential thrombocythemia with symptomatic internal carotid artery stenosis: a case report
by: Minghui Du, et al.
Published: (2025-08-01)

Exogenous Janus Kinase 617 Codon Influences Small Noncoding RNAs and Gene Expression in Ba/F3 Cells
by: Yi-Yang Chen, et al.
Published: (2024-12-01)

Prevalence and clinicopathological features of driver gene mutations profile in BCR:ABL1 negative classical myeloproliferative neoplasm—A single-center study from North India
by: Khaliqur Rahman, et al.
Published: (2024-12-01)

CalR and MPL Driver Mutations and Their Role in the Diagnosis and Clinical Course of JAK2-Unmutated Chronic Myeloproliferative Neoplasm: Results from a Pilot Single-Center Study
by: Tarık Onur Tiryaki, et al.
Published: (2025-05-01)

Potential application of the bulk RNA sequencing in routine MPN clinics
by: Shenglong Li, et al.
Published: (2025-04-01)

Gender and age characteristics of <I>JAK2</I> V617F mutation allelic burden and <I>CALR</I> and <I>MPL</I> driver mutations detection during primary examination of patients with suspected myeloproliferative neoplasms
by: I. A. Olkhovskiy, et al.
Published: (2024-12-01)

WT1 Gene Overexpression in Differential Diagnosis of Ph-negative Myeloproliferative Disorders
by: EG Lomaia, et al.
Published: (2019-05-01)

Chilblains as a Clue for the Diagnosis of Essential Thrombocythemia
by: Hugo J. Leme, et al.
Published: (2025-05-01)

Current Genetic Models for Prediction of Primary Myelofibrosis
by: LB Polushkina, et al.
Published: (2019-09-01)

The CHIP-clinic as the catalyst of preventive medicine
by: Hans Carl Hasselbalch, et al.
Published: (2024-10-01)

CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL
by: Vincenzo Accurso, et al.
Published: (2020-01-01)

Myelodysplastic/myeloproliferative neoplasm with t(2;11)(p21;q23)del(5) (q22;q33) but without mixed-lineage leukemia (MLL) rearrangement
by: Čolović Nataša, et al.
Published: (2021-01-01)

Masked polycythemia vera manifested by splanchnic venous thrombosis during pregnancy: a clinical case
by: M. Yu. Nadinskaia, et al.
Published: (2022-05-01)

Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blast-phase myelofibrosis
by: M. S. Fominykh, et al.
Published: (2016-08-01)

Comprehensive evaluation of coagulability using thromboelastography in four patients with essential thrombocythemia
by: Shuji Kawamoto, et al.
Published: (2025-05-01)

How we treat polycythemia vera
by: V. A. Shuvaev, et al.
Published: (2024-01-01)

Perspectives for next generation sequencing in patients with follicular lymphoma
by: E. O. Kunevich, et al.
Published: (2023-12-01)

The Levels of Adhesion Molecules in Essential Thrombocythemia
by: Oktay Bilgir, et al.
Published: (2014-08-01)

Essential Thrombocythemia Masquerading as Henoch–Schonlein Purpura in a 9-year-old Child
by: Palanisamy Sivamurukan, et al.
Published: (2020-01-01)

THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION
by: Emmanouil Spanoudakis, et al.
Published: (2018-10-01)

Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan
by: Yoko Edahiro, et al.
Published: (2024-12-01)

Targeted Therapy of Myelofibrosis
by: OYu Vinogradova, et al.
Published: (2017-10-01)

Informative Value of Combination of Molecular Genetic and Cytogenetic Diagnostic Methods in Myelofibrosis
by: Lozynskyy R., et al.
Published: (2016-07-01)

Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study
by: O. Yu. Vinogradova, et al.
Published: (2024-09-01)

Biology of Myeloproliferative Malignancies
by: AL Melikyan, et al.
Published: (2016-07-01)

The characteristics of CALR mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review
by: Mostafa Najim, et al.
Published: (2024-12-01)

A focal extramedullary hematopoiesis of the spleen in a patient with essential thrombocythemia presenting with a complicated postoperative course: a case report
by: Kiyotaka Hosoda, et al.
Published: (2021-01-01)

Insights into the role of JAK2-I724T variant in myeloproliferative neoplasms from a unique cohort of New Zealand patients
by: Christopher Puli'uvea, et al.
Published: (2024-12-01)

Cecal cancer with essential thrombocythemia treated by laparoscopic ileocecal resection: a case report
by: Masaya Hiyoshi, et al.
Published: (2019-06-01)